• DOI:10.3928/23258160-20170329-03
• Corpus ID: 5418288

Use of Corticosteroids in the Treatment of Patients With Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel.

@article{Regillo2017UseOC,
  title={Use of Corticosteroids in the Treatment of Patients With Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel.},
  author={Carl D. Regillo and David G. Callanan and Diana V. Do and Howard F. Fine and Nancy Holekamp and Baruch D. Kuppermann and Michael A Singer and Rishi P. Singh},
  journal={Ophthalmic surgery, lasers \& imaging retina},
  year={2017},
  volume={48 4},
  pages={
          291-301
        }
}

• C. Regillo, D. Callanan, +5 authors Rishi P. Singh
• Published 1 April 2017
• Medicine
• Ophthalmic surgery, lasers & imaging retina

BACKGROUND AND OBJECTIVE
Guidance on the use of corticosteroids in the treatment of diabetic macular edema (DME) is lacking. This study aimed to develop a clinically recommended treatment paradigm for DME with emphasis on the role of corticosteroids.

PATIENTS AND METHODS
An expert panel of nine retinal specialists in the United States developed consensus recommendations for DME treatment through a modified Delphi process.

RESULTS
The panelists typically use intravitreal injections of vascular endothelial growth factor (VEGF) antagonists as first-line treatment of DME and switch patients with an inadequate response to anti-VEGF therapy (failure of best-corrected visual acuity to improve to 20/40 or better because of edema after three to six monthly injections, or a less-than-50% reduction in excess macular thickness after three to four monthly injections) to intravitreal corticosteroid treatment.

CONCLUSION
Intravitreal corticosteroids have a potentially useful role in the treatment of patients with DME who have an inadequate response to intravitreal anti-VEGF therapy. [Ophthalmic Surg Lasers Imaging Retina. 2017;48:291-301.].